CRVS:NASDAQCorvus Pharmaceuticals, Inc. Analysis

Corvus Pharmaceuticals (CRVS) is trading at $13.26, just above its calculated support at $12.53 and well below the 20‑day SMA of 14.38, while the 50‑day (13.26) and 200‑day (12.96) SMAs sit beneath the current price, creating a classic bullish SMA hierarchy. The technical picture is mixed: the MACD line sits below its signal (‑0.188 vs 0.034) and the histogram is negative, signaling short‑term bearish momentum, yet the overall trend direction is flagged as bullish and the RSI at 44 is neutral. Volume is on a decreasing trend, and 30‑day volatility is elevated at 52%, indicating price swings can be sharp. A negative beta (‑0.51) suggests the stock may move opposite to the broader market, adding a layer of defensive behavior but also uncertainty.
Fundamentally, CRVS is a clinical‑stage biotech with no revenue and negative earnings (trailing EPS –0.55, forward EPS –0.965), but it holds a strong cash position of $236 M against modest debt ($0.8 M) and a debt‑to‑equity of 0.35. The price‑to‑book ratio of 4.63 is high for a cash‑burning company, and the forward P/E of –13.7 reflects ongoing losses. Nonetheless, analysts rate the stock as a “strong buy” (7 analysts) with a median target of $32 and a mean target of $33.14, implying a potential upside of roughly 150% from current levels. No dividend is paid, confirming that dividend sustainability is not a factor. The combination of a sizable cash runway, promising pipeline candidates, and aggressive analyst price targets makes the stock appear significantly undervalued despite its high clinical and regulatory risk profile.